Sugi Predict

Sugi Predict / Compounds / SCHEMBL1064642

SCHEMBL1064642

SCHEMBL1064642

CCOC(=O)[C@@H](N)Cc1ccc(F)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 2/20 0.51
▸ EPHX2 P34913 1/20 0.51
▸ MAPT P10636 4/20 0.45
▸ MEN1 O00255 3/20 0.45
▸ KMT2A Q03164 3/20 0.45
▸ LMNA P02545 2/20 0.45
▸ NPSR1 Q6W5P4 2/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ ALOX12 P18054 1/20 0.45
▸ CCR6 P51684 1/20 0.45
▸ HKDC1 Q2TB90 1/20 0.45
▸ KDM4C Q9H3R0 1/20 0.45
▸ CYP1A2 P05177 1/20 0.44
▸ CYP2C9 P11712 1/20 0.44
▸ CYP2C19 P33261 1/20 0.44
▸ TPH1 P17752 4/20 0.43
▸ DPP4 P27487 2/20 0.43
▸ TRPA1 O75762 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL839736 1.00 PPARG (0.51) PPARGEPHX2MAPTMEN1KMT2A
SCHEMBL838697 1.00 PPARG (0.51) PPARGEPHX2MAPTMEN1KMT2A
Hydrochloric Acid SCHEMBL2108091 0.98 PPARG (0.50) PPARGEPHX2MAPTMEN1KMT2A
Hydrochloric Acid SCHEMBL1064640 0.98 PPARG (0.50) PPARGEPHX2MAPTMEN1KMT2A
SCHEMBL7224977 0.95 DPP4 (0.49) PPARGEPHX2MAPTMEN1KMT2A
Hydrochloric Acid SCHEMBL7224972 0.94 DPP4 (0.48) PPARGEPHX2MAPTMEN1KMT2A
SCHEMBL7960935 0.91 SLC7A5 (0.48) PPARGEPHX2ALDH1A1TPH1SLC7A5
SCHEMBL9967935 0.86 SLC7A5 (0.44) PPARGMAPTMEN1KMT2ALMNA
SCHEMBL20543461 0.86 SLC7A5 (0.44) PPARGMAPTMEN1KMT2ALMNA
SCHEMBL21117856 0.86 SLC7A5 (0.44) PPARGMAPTMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011078782-A1 A COMPOSITION COMPRISING OF MELPHALAN DERIVATIVES AND GEMCITABINE OR ETOPOSIDE USEFUL IN THE TREATMENT OF CANCER ONCOPEPTIDES AB (SE) 2011-06-30 — — WO claimed
US-12558337-B2 Formulations comprising melflufen ONCOPEPTIDES INNOVATION AB (SE) 2026-02-24 — — US disclosed
US-20260021067-A1 TREATMENT OF AL AMYLOIDOSIS WITH MELFLUFEN ONCOPEPTIDES AB (SE) 2026-01-22 — — US disclosed
US-12396975-B2 Treatment of al amyloidosis with melflufen ONCOPEPTIDES AB (SE) 2025-08-26 — — US disclosed
US-20250205155-A1 FORMULATIONS COMPRISING MELPHALAN FLUFENAMIDE AND CYCLODEXTRIN ONCOPEPTIDES INNOVATION AB (SE) 2025-06-26 — — US disclosed
CN-112930214-B Deuterium containing compounds 肿瘤多肽创新股份公司 2025-05-16 — — CN disclosed
US-20250144023-A1 MELFLUFEN DOSAGE REGIMENS FOR CANCER ONCOPEPTIDES INNOVATION AB (SE) 2025-05-08 — — US disclosed
US-20250144023-A1 MELFLUFEN DOSAGE REGIMENS FOR CANCER ONCOPEPTIDES INNOVATION AB (SE) 2025-05-08 — — US disclosed
US-20250115637-A1 COMPOUNDS CONTAINING DEUTERIUM ONCOPEPTIDES INNOVATION AB (SE) 2025-04-10 — — US disclosed
EP-4499049-A1 FORMULATIONS COMPRISING MELPHALAN FLUFENAMIDE AND CYCLODEXTRIN Oncopeptides Innovation AB (SE) 2025-02-05 — — EP disclosed
EP-1129107-A1 METHOD FOR PRODUCING L-PROLYL-L-M-SARCOLYSYL-L-P-FLUOROPHENYLALANINE AND DERIVATIVES THEREOF PTC Pharma AG (CH) 2001-09-05 — — EP disclosed
WO-2000031119-A1 METHOD FOR PRODUCING L-PROLYL-L-M-SARCOLYSYL-L-P-FLUOROPHENYLALANINE AND DERIVATIVES THEREOF PTC PHARMA AG (CH) 2000-06-02 — — WO disclosed
EP-1001799-A1 PHARMACEUTICAL COMPOSITION CONTAINING PEPTICHEMIO Peptichemio AG (CH) 2000-05-24 — — EP disclosed
EP-0866705-A4 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO INC (US) 1999-03-03 — — EP disclosed
WO-1999002177-A1 PHARMACEUTICAL COMPOSITION CONTAINING PEPTICHEMIO PEPTICHEMIO AG (CH) 1999-01-21 — — WO disclosed
US-5852045-A Fibrinogen receptor antagonists MERCK & CO., INC. (US) 1998-12-22 — — US disclosed
EP-0866705-A1 FIBRINOGEN RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 1998-09-30 — — EP disclosed
WO-1997014417-A1 FIBRINOGEN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 1997-04-24 — — WO disclosed
US-4857553-A SIDE EFFECT REDUCTION A. H. ROBINS COMPANY, INCORPORATED (US) 1989-08-15 — — US disclosed
EP-0302757-A2 Anti-emetic serotonin depleting agents A.H. ROBINS COMPANY, INCORPORATED (US) 1989-02-08 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12396975-B2 Treatment of al amyloidosis with melflufen MME, TTR, MLLT1 PPARG 3856/4885EPHX2 2308/4885MAPT 202/4885
US-12558337-B2 Formulations comprising melflufen PHF8, EZH2, PHF2 PPARG 2141/4885EPHX2 2824/4885MAPT 1823/4885
US-20260021067-A1 TREATMENT OF AL AMYLOIDOSIS WITH MELFLUFEN MME, MYOF, TTR PPARG 3643/4885EPHX2 3384/4885MAPT 625/4885
US-20250205155-A1 FORMULATIONS COMPRISING MELPHALAN FLUFENAMIDE AND CYCLODEXTRIN FUCA1, FGF2, FUCA2 PPARG 3744/4885EPHX2 2554/4885MAPT 2538/4885
US-20250144023-A1 MELFLUFEN DOSAGE REGIMENS FOR CANCER MME, SLC43A1, SLC7A5 PPARG 3775/4885EPHX2 1944/4885MAPT 3827/4885
US-20250115637-A1 COMPOUNDS CONTAINING DEUTERIUM DHX30, H1-10, REN PPARG 2897/4885EPHX2 3372/4885MAPT 3108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.